Aptar Pharma Teams Up with Pulmotree To Launch Game-Changing Liquid Inhaler

Aptar Pharma, a global frontrunner in drug delivery and active material science, has unveiled an exclusive partnership with PULMOTREE. This collaboration will focus on advancing and marketing PULMOTREE's Kolibri™ Non-Propellant Liquid Inhaler (NPLI) platform. Under this agreement, Aptar Pharma will offer extensive support to PULMOTREE, serving as the primary contact for clients and enhancing the Kolibri™ NPLI Platform Technology with Aptar’s range of services.

Non-Propellant Liquid Inhalers, including nebulizers and soft-mist inhalers, are emerging as alternatives to traditional propellant-based systems. PULMOTREE’s Kolibri™ stands out with its cutting-edge breath-triggered Vibrating Mesh technology and breath-guidance features, aimed at improving targeted lung delivery. The Kolibri™ has garnered awards and integrates advanced connectivity features.

This partnership further cements Aptar Pharma's leadership in the respiratory field by expanding their portfolio of drug delivery formats, solutions, and services. By utilizing the expertise of Aptar Pharma's network—including Nanopharm’s formulation and analytical skills, Noble’s Human Factors and patient onboarding support, and Aptar Digital Health’s services—Aptar Pharma can offer tailored drug formulation, optimize device design, and enhance patient outcomes, ultimately delivering added value to their customers.

Howard Burnett, Vice President, Global Pulmonary Category, Aptar Pharma, said, “Pulmotree has solid experience in the NPLI field and Aptar Pharma is delighted to be able to offer the Kolibri™ technology in collaboration with such a knowledgeable partner, to be able to provide full support to all drug developers, from formulation development to patient onboarding.”

Ulf Krüger, CEO of PULMOTREE, mentioned, “With this alliance, pharmaceutical partners can access an unprecedented portfolio of services from Aptar Pharma as a single source, in the development of combination products to accelerate product development. For PULMOTREE, this important step enables us to continue to grow sustainably and expand our portfolio.”

Howard Burnett added, “With this partnership, Aptar and PULMOTREE can provide a unique offer to the market to tune and tailor both formulation and delivery system seamlessly, and support drug development, to enable intuitive and efficient delivery in the hands of patients.”